Prednisone

Generic Name: Prednisone

Brand Names: Deltasone, Rayos, Winpred

Drug Type: Small Molecule

Chemical Formula: C_₂₁H_₂₆O_₅

CAS Number: 53-03-2

Unique Ingredient Identifier: VB0R961HZT

Background: A synthetic anti-inflammatory glucocorticoid derived from cortisone. It is biologically inert and converted to prednisolone in the liver.

Prednisone was granted FDA approval on 21 February 1955.

Indication: Prednisone is indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant.

Associated Conditions: Acne Vulgaris, Acute Exacerbation of Chronic Obstructive Pulmonary Disease, Acute Gouty Arthritis, Acute Leukemia, Aggressive Lymphoma, Allergic Bronchopulmonary Aspergillosis, Allergic Conjunctivitis (AC), Allergic Rhinitis (AR), Allergic corneal marginal ulcers, Alveolitis, Extrinsic Allergic, Ankylosing Spondylitis (AS), Aspiration Pneumonitis, Asthma, Atopic Dermatitis, Autoimmune Hepatitis, Bell's Palsy, Berylliosis, Bullous dermatitis herpetiformis, Chorioretinitis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Contact Dermatitis, Disseminated tuberculosis, Drug hypersensitivity reaction, Edema of the cerebrum, Epicondylitis, Erythroblastopenia, Giant Cell Arteritis (GCA), Hypercalcemia of Malignancy, Idiopathic Pulmonary Fibrosis (IPF), Immune Thrombocytopenia (ITP), Iridocyclitis, Iritis, Keratitis, Leukemias, Loeffler's syndrome, Lymphoma, Meningitis caused by Mycobacterium Tuberculosis, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Mycosis Fungoides (MF), Ocular Inflammation, Ophthalmia, Sympathetic, Optic Neuritis, Pain caused by Herpes zoster, Pemphigus, Pericarditis, Pneumocystis Jirovecii Pneumonia, Polymyalgia Rheumatica (PMR), Polymyositis, Posterior Uveitis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Regional Enteritis, Relapsing Polychondritis, Rheumatoid Arthritis, Rheumatoid Arthritis, Juvenile, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Serum Sickness, Severe Seborrheic Dermatitis, Sjogren's Syndrome (SS), Solid Organ Transplant Rejection, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Thyroid Eye Disease, Thyroiditis, Thyrotoxicosis, Trichinosis, Ulcerative Colitis, Uveitis, Vasculitis, Acquired immune hemolytic anemia, Acute Bursitis, Acute Crohn's Disease (CD), Acute Multiple sclerosis exacerbation, Acute rheumatic carditis, Anterior eye segment inflammation, Exfoliative erythroderma, Fulminating Tuberculosis, Idiopathic Bronchiolitis obliterans with organizing pneumonia, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Psoriasis, Subacute Bursitis, Symptomatic Sarcoidosis, Synovitis of osteoarthritis, Systemic Dermatomyositis, Varicella-zoster virus acute retinal necrosis

Associated Therapies: Palliative Treatment

Clinical Trials

Comparison of Docetaxel/Prednisone to Docetaxel/Prednisone in Combination With OGX-011 in Men With Prostate Cancer

Phase 3

Completed

Conditions: Prostate Cancer

Interventions: Drug: Custirsen
Drug: Docetaxel
Drug: Prednisone
Drug: Dexamethasone

First Posted Date: 2010-08-25

Last Posted Date: 2016-10-14

Lead Sponsor: Achieve Life Sciences

Target Recruit Count: 1022

Registration Number: NCT01188187

Locations: 🇳🇱
Teva Investigational Site 852, Rotterdam, Netherlands
🇺🇸
Teva Investigational Site 093, Marina del Rey, California, United States
🇺🇸
Teva Investigational Site 100, Birmingham, Alabama, United States

and more 137 locations

EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)

Phase 1

Terminated

Conditions: Lymphoblastic Leukemia, Acute
Leukemia, Lymphoblastic, Acute
Lymphoblastic Leukemia, Acute, Childhood
Leukemia, Lymphoblastic, Acute, T Cell

Interventions: Drug: EZN-3042
Drug: Cytarabine
Drug: Doxorubicin
Drug: Prednisone
Drug: Vincristine
Drug: PEG-asparaginase
Drug: Methotrexate
Drug: Hydrocortisone

First Posted Date: 2010-08-23

Last Posted Date: 2024-02-01

Lead Sponsor: Therapeutic Advances in Childhood Leukemia Consortium

Target Recruit Count: 6

Registration Number: NCT01186328

Locations: 🇦🇺
Sydney Children's Hospital, Sydney, Australia
🇺🇸
St. Jude, Memphis, Tennessee, United States
🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States

and more 4 locations

An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens

Phase 4

Completed

Conditions: Comparative Study
Immunosuppressive Agents

Interventions: Drug: Everolimus
Drug: Prednisone
Drug: Rapamycin

First Posted Date: 2010-08-17

Last Posted Date: 2010-08-17

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 63

Registration Number: NCT01183247

Locations: 🇨🇭
Clinic for transplantation immunology and nephrology, Basel, Switzerland

Effectiveness in Daily Practice of Different Treatment Strategies for Early Rheumatoid Arthritis.

Phase 4

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: Methotrexate
Drug: Sulfasalazine
Drug: Prednisone
Drug: Leflunomide

First Posted Date: 2010-07-30

Last Posted Date: 2019-01-22

Lead Sponsor: P. Verschueren

Target Recruit Count: 400

Registration Number: NCT01172639

Locations: 🇧🇪
Reuma instituut Hasselt, Hasselt, Belgium
🇧🇪
ZNA Jan Palfijn, Merksem, Belgium
🇧🇪
Henri Serruys ziekenhuis, Oostende, Belgium

and more 14 locations

Short Term Efficacy of a Starting Dose of 12.5 mg of Prednisone in Polymyalgia Rheumatica Patients

Phase 4

Completed

Conditions: Polymyalgia Rheumatica

First Posted Date: 2010-07-26

Last Posted Date: 2010-07-26

Lead Sponsor: University of Genova

Target Recruit Count: 60

Registration Number: NCT01169597

Locations: 🇮🇹
Clinica Reumatologica, Dipartimento di medicina Interna, Università di Genova, Genova, Italy

Study the Relationship Between Obesity and Hepatitis C Replication

Phase 2

Withdrawn

Conditions: Hepatitis C

Interventions: Drug: Pioglitazone
Drug: Prednisone

First Posted Date: 2010-07-08

Last Posted Date: 2019-12-02

Lead Sponsor: University of California, San Diego

Registration Number: NCT01157975

Locations: 🇪🇬
Agouza Hospital, Giza, Egypt
🇺🇸
University of California at San Diego Hospitals, San Diego, California, United States

Combination Chemotherapy in Treating Young Adult Patients With Acute Lymphoblastic Leukemia

Not Applicable

Completed

Conditions: Leukemia

First Posted Date: 2010-07-05

Last Posted Date: 2021-09-13

Lead Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto

Target Recruit Count: 76

Registration Number: NCT01156883

Locations: 🇮🇹
Azienda Ospedaliera - Nuovo Ospedale "Torrette", Ancona, Italy
🇮🇹
USL 8 - Ospedale S.Donato, Arezzo, Italy
🇮🇹
UO Ematologia con trapianto- AOU Policlinico Consorziale di Bari, Bari, Italy

and more 40 locations

Phase I Sodium Selenite in Combination With Docetaxel in Castration-resistant Prostate Cancer

Phase 1

Terminated

Conditions: Prostate Cancer Metastatic Disease
Prostate Cancer
Urologic Neoplasms

Interventions: Drug: Docetaxel
Drug: Biosyn
Drug: Prednisone

First Posted Date: 2010-07-02

Last Posted Date: 2017-03-15

Lead Sponsor: Sandy Srinivas

Target Recruit Count: 2

Registration Number: NCT01155791

Locations: 🇺🇸
Stanford University School of Medicine, Stanford, California, United States

R-CHOP Versus R-mini-CEOP in Elderly Patients(>65)With DLBCL

Phase 3

Completed

Conditions: Elderly Patients (>65 Years)
Diffuse Large B Cell Lymphoma (DLBCL)

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Epirubicin
Drug: Vincristine
Drug: Prednisone
Drug: Vinblastine
Drug: Rituximab
Drug: G-CSF

First Posted Date: 2010-06-22

Last Posted Date: 2010-06-22

Lead Sponsor: Fondazione Italiana Linfomi - ETS

Target Recruit Count: 226

Registration Number: NCT01148446

Locations: 🇮🇹
Ospedale San Sebastiano, Correggio (RE), Italy
🇮🇹
Istituto Vito Fazzi, Lecce, Italy
🇮🇹
S.C. di Ematologia, Spedali Civili, Brescia, Italy

and more 8 locations

Docetaxel and Prednisone With or Without Vaccine Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Phase 2

Terminated

Conditions: Hormone-Resistant Prostate Cancer
Prostate Adenocarcinoma
Recurrent Prostate Carcinoma
Stage IV Prostate Cancer

Interventions: Drug: Docetaxel
Other: Laboratory Biomarker Analysis
Drug: Prednisone
Biological: Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine
Biological: Rilimogene Galvacirepvec

First Posted Date: 2010-06-16

Last Posted Date: 2017-09-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 10

Registration Number: NCT01145508

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Mayo Clinic in Florida, Jacksonville, Florida, United States

and more 11 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy